Welcome to Investors’ Day

June 23, 2022
©TERUMO CORPORATION

1

Table of Contents
 Executive Management Committee Introduction
 Strategic Vision and Growth Strategy
 Business Overview
 Plasma Innovations Ecosystem Wrap Up©TERUMO CORPORATION

2Executive Management Committee
We have invested in talent to support our aspirations

Chetan Makam
Blood Center
Solutions

Veerle d’Haenens
TherapeuticSystems

Cindy Ng
Global Sales &Services©TERUMO CORPORATION

Delara Motlagh
Cell Therapy
Technologies

Chris Williams
GlobalManufacturing

Cynthia Hougum
Plasma Innovations

Bon Lopez
Human Resources

John Tanner
Strategy,Market Access &Innovation

Rebecca Bortolotti
General Counsel &Government Affairs

3

Gene Stellon
Research &Development

Rusty Spinney
Chief Financial
Officer Recruited seasoned
leaders to create marketdriven innovation andunleash enterprisesynergies
 Promoted proven internaltalent to build businessecosystems for next stageof growth Extended our depth inGovernment Affairs,
Market Access andRegulatory

Strategic Vision
Our Aspiration
 Provide compelling and accessible innovations globally thatunlock the power of blood and cells to improve patient
outcomes and serve unmet medical needs

How this will be achieved
 By inspiring and engaging our associates, we will optimize
quality and deliver world-class solutions, earning customer
loyalty and setting industry standards

GS26 Financial Aspiration
 Sales : Near Double Digit Growth Adjusted Operating Profit: Beyond 20%©TERUMO CORPORATION

4

Returned to Growth – Revenue and Profit
Historical Operating Performance

Transformational Shifts

US$ in Millions

0.0%
$872

8.8%

$944

0.2%

4.2%

$946 $872 $986

4.7%
$1032

4.0%

 Shifted investment to growth areas
 Diversified beyond equipment and blood Built infrastructure in growth geographies$1073

 Sharpened strategic focus in services
 Modernize infrastructure

49%

49%

49%

48%

51%

 Optimized manufacturing footprint49%

 Implemented one global quality system Adopted SFDC and Service Max globally

Adjusted
14%

14%

15%

14%

18%

17%

FY16

FY17

FY18

FY19

FY20FY21

 Continue investing ~12% of sales in R&D

FY 16-19 at actual FX rates; FY 20-21 at FY 21 Plan FX rates©TERUMO CORPORATION

5

Met Growth Targets and Continued Our Transformation Despite COVID
Our Commitment

1Protect
OurAssociates

 Safety
 Security
 Mental Health

2ServeCustomersand Patients

 Flexed production to serve patient
hot spots

 Prioritized programs to buildcontingency

 Developed COVID solutions

 Rationalize capital spend First Emergency Use Authorization forOptia/Marker
 Led industry adoption of convalescentplasma Showed relevance of Mirasol
pathogen reduction©TERUMO CORPORATION

3ConserveCash6

 Modernized infrastructure

Operations Transformation

Shifting production to build customer delivery flexibility while lowering costs

Larne, Ireland• Products: Solutions• Markets: Global/CMOLittleton, US NEW• Products: Plasma• Markets: USLakewood, USFujinomiya, Japan• Products: Devices and Disposables• Markets: Global• Products: Blood Bags, Filters• Markets: JapanVietnam
Trivandrum, India

Costa Rica NEW• Products: Blood Bags/Reveos• Markets: LatAm, EU• Expanded capacity +20%

• Products: Trima/Optia/Others• Markets: Global• Transfer Lakewood
disposable production andincreased capacity +20%

©TERUMO CORPORATION

7• Products: Trima, Blood Bags, Reveos• Markets: Global• Completed vertical integration andcreated available capacity +30%

Newly Built Costa Rica Facility

Bringing the best of our global manufacturing design and processes

 Costa Rica is a proven hub for theproduction of medical devices
 World-class facility - increased
capacity to serve global markets
 Excellent talent and supply chain
infrastructure, strategically close tocustomers in the Americas
 Concept to full ramp in record time

©TERUMO CORPORATION

8Market Dynamics Inform Strategic Choices
Market Dynamics

Strategic Implications

 Changing demographics

 Donor shortages and shifts
 Increase in chronic disease Disease & patient data enabling
personalized medicine

 Data integration expected Clinical efficacy required Growing regulatory cost burden Rationalize portfolio
 Innovate beyond equipment

 Commercialization of celltherapies

 Follow shift in investment:
scale, logistics & patient access Cost of care plays a greater rolein healthcare policy Reimbursement key to change
standards & increase access©TERUMO CORPORATION

9Aligning Investments with Growth Areas
Estimated Growth Rate*

Create | Disrupt
Whole BloodAutomation

Cell Therapy

PlasmaInnovations

Focus | ReframeTherapeutic
Apheresis

Autologous
Biologics

AutomatedCollection= FY21Plan;©TERUMOCORPORATION

5%5%

Optimize

Legend:20%Contract
Blood
Whole BloodCore
Manufacturing Safety

10 estimates for illustrative purposes= FY26 sales; size of circles reflects relative sales levels. * Internal

Blood Centers Solutions

Shape the Future Across a Diverse Care Continuum

Unmet local needs inform unique business models and growth in the core blood businessContinuum of Transfusion Therapies❶ Recruit❷ Collect❸ Process❹ Deliver❺ Treat

Leapfrog in underserved markets

Transform Advanced Blood Centers Manual Unsafe
 Supply shortage

 Undifferentiated©TERUMO CORPORATION

Automated process
Pathogen reduction“Blood center in a box”
Investment inGovernment Affairs

11

blood supplier tohospitals

 Blood as a therapy
 Expanded to cellcollections and apheresis
Sickle cell disease treatment

Blood Centers Solutions

Building for the Future

Equipment and beyond: Areas of exploration and investment

Veda Solutions

Advancing automation
as a global standard©TERUMO CORPORATION

Going beyond devices withservices and clinical insights
12Data enables efficiencies
and decision-making

Therapeutic Systems

Enhancing Access to Therapies That Serve Unmet Medical Needs
Improving options in the care journey for sickle cell disease

Every year, about 300,000 newborns are diagnosed
with sickle cell disease

Synergies
with drug
options
Automated
red blood cellexchange

Cell andgene
therapies

Rona Wiggins, Sickle Cell Disease Patient©TERUMO CORPORATION

13Illustration only

Therapeutic Systems

Transforming Therapy Options for Patients with Triple-Negative Breast Cancer
Collaborations reinforce the diversity and power of the Spectra Optia platform

Each year there are over 2 million newly
diagnosed breast cancer patients worldwide

Immunotherapies
Immunopheresis®

Chemotherapy©TERUMO CORPORATION

14Illustration only

Cell Therapy Technologies

Bridging Clinics and Biotechs to Increase Therapy AccessFacilitate the journey of life-saving cells from patient collection through the ultimate transfusion
Patient Journey
Cell Collection
and Preparation

Testing andPatient Coordination
Testing &Collection Center

Local Hospital

Veda Solutions & Stafa

Therapy Delivery
Logistics
Therapy preparation

Cell Journey

Emily Whitehead, first child in the world to have immune cells
activated to fight cancer. Photo by Emily Whitehead Foundation.

©TERUMO CORPORATION

15Manufacturing(Pharma, CMO)

Cell Therapy
Manufacturing

Cell Therapy Technologies

Investing to Shape the Cell Therapy Ecosystem

Support biotechs with holistic solutions to make innovative therapies accessible to more patients
Biotechs
CDMOs

Global drug developers

Cell Collection

Cell Manufacturing

Service and Data

Standardized cell products andbetter patient experience

Scalable solution for high quality cells
and faster cycle time

Customized services for processoptimization and data management©TERUMO CORPORATION16Plasma Innovations

Pete Atherton

Common Variable Immune
Deficiency Patient, USA

Unlocking our potential to provide
compelling and accessible innovations
to serve unmet medical needs globally©TERUMO CORPORATION Long journey to diagnosis and lack of access to medicines One patient requires multiple donations per year
 85% of plasma is procured from the US, Germany and China17

Innovating in the Source Plasma Market
Optimizing the donor experience and operational efficiencies

Rika
Plasma Donation System

Integrated Supply
Chain and Distribution

Kinari
Device Management Platform

Built Ecosystem
to Meet Unmet
Market Needs

State-of-the-ArtAutomated
Manufacturing©TERUMO CORPORATION

MyataCustomer Service Portal

Training & Simulation
Modules18

Rika Plasma Donation System

An ecosystem designed to advance the plasma market

 Designed for the “-abilities”
 Focused on usability and donor cycle time Integrates plasma collection technology, datasolutions, services and program support©TERUMO CORPORATION

19

Innovation Centered in the Donor Experience
Comfort and safety at the core

 Donation completed in 35 minutes or less Intelligent donation – Rika senses the donor Real-time status of donation progress No more than 200 mL of blood outside thebody at any time Designed to encourage repeat donations

Plasma collection during the Rika clinical trial. Photo provided by CSL Plasma.

©TERUMO CORPORATION

20

Positioned to Innovate the Source Plasma Market and Beyond
Investment that will inform the next generation of innovation across the businesses

Rika
Plasma Donation System

Integrated Supply
Chain and Distribution

Kinari
Device Management Platform

Built Ecosystem
to Meet Unmet
Market Needs

State-of-the-Art
Automated
Manufacturing©TERUMO CORPORATION

MyataCustomer Service Portal

Training & Simulation
Modules21

Infrastructure to support Plasma Innovations Ecosystem

 New state-of-the-art factory in Littleton, Colorado
State-of-the-Art
AutomatedManufacturing

 Automated assembly, packaging, and quality inspection

 Support the ramp of new contract manufacturing Built production departments at two contract manufacturers

Built Ecosystem
to Meet Unmet
Market Needs

for devices and bottles

 Integrated Supply Chain and Distribution
Integrated Supply
Chain and Distribution©TERUMO CORPORATION

 Support more efficient vendor management of disposables
inventory22

Look Out and Forward to Transform our Profit Profile
Shifting investment to growth programs while improving margins

High Profit, High Growth Market Entry
 Plasma Innovations

Adjusted Operating Profit Aspiration(M USD at FY21 Plan FX Rate FY20-26)

~20%

17%

17%

14%

 Capture value from innovation through whole
blood automation, cell therapy technology andtherapeutic collaborations
 Expand services and software Represent full portfolio in emerging markets
Materially Capture Value of Investment
 Transform operations to offset inflation
 Leverage data infrastructure to lean processes
 R&D velocity and impact

Core Business: MUSD @ FY21 FX rates excluding Plasma and Costa Rica Impacts©TERUMO CORPORATION

Optimize Profit Contribution from ExistingPortfolio

23

5-Year Growth Strategy: Terumo Blood and Cell Technologies
Strategic investments transform our portfolio and profit potential

Blood andBeyond

Equipment
and Beyond

GeographicExpansion

Operational
Excellence Transform the source
plasma industry​ Differentiate withService offerings

 Optimized global
delivery system

 New therapies forchallenging diseases

 Following thepatient to inform
innovation

 Bring safe blood
everywhere –Africa, China

 Optimize cellcollections and enable  Closed
cell therapyloop analytics tomanufacturing
improve patientoutcomes©TERUMO CORPORATION Expand whole
blood automation
 Increase accessto therapeutictreatment24

 Localize,standardize Capture thecommercial valueof our innovation

Unlocking our Potential to Serve More Patients

Multiple Myeloma©TERUMO CORPORATION

Sickle Cell Disease

Acute Lymphoblastic Leukemia

25

Common Variable Immune Deficiency

©TERUMO CORPORATION26